A lab technician uses a pipette dropper during the antigen quantification process of the coronavirus vaccine research at the Valneva SA laboratories in Vienna, Austria, on Thursday, Aug. 6, 2020. T
Akos Stiller/Bloomberg News
Pharmaceutical group Pfizer Inc. said its Covid-19 vaccine candidate, being developed jointly with BioNTech SE, was on track for regulatory review as early as October as it released more data on the product.
The companies on Thursday released additional data from their ongoing study of the BNT162b2 mRNA-based vaccine that is in now a phase 2/3 trial in the U.S. and Germany.
The data showed the vaccine candidate’s “promising safety and immunogenicity profile” from the Phase 1 U.S. trial, said Kathrin Jansen, head of vaccine research and development at Pfizer. Immunogenicity refers to a vaccine’s ability to trigger an immune response in individuals.
Jansen said the company would share T-cell immune response data from the German trial in the near future.
Across younger and older adults it tested, the potential treatment was “well tolerated with mild to moderate fever in fewer than 20%” of participants, they said.
Pfizer PFE,
Read: A tidal wave of vaccine news is hitting the market
Pfizer’s update helped boost Asian equities on Friday, with S&P 500 futures ES00,
Read: CureVac and EU in advanced talks for 225 million Covid-19 vaccine doses
Pfizer and BioNTech have involved 30,000 participants in the late-stage trial of its Covid-19 candidate that began in late July. The companies previously announced they would receive $ 1.95 billion from the U.S. government to produce at least 100 million doses of their experimental vaccine.
Pifzer shares have lost 1% since the start of the year, while BioNTech shares have rallied 95%.
